Drug intelligence / Profile preview

RJ015

Development stage: Preclinical
Lead developer: Risen
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RJ015 is a small interfering RNA (siRNA) therapeutic candidate currently in preclinical development by Risen Shanghai Medical Technology (Risen Pharma). It is being developed for the treatment of metabolic diseases. As an siRNA molecule, RJ015 is designed to utilize the RNA interference (RNAi) pathway to silence the expression of a specific gene involved in metabolic dysfunction. While the company has disclosed its modality and primary therapeutic area, the specific molecular target of RJ015 remains undisclosed.

Beyond the preview

Go deeper on RJ015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ015.

Explore the full profile